In addition, FTO depletion contributes to increased sensitivity to interferon gamma (IFNγ) and anti-PD-1 by enhancing m6A-modified PD-1, CXCR4, and SOX10 degradation in melanoma cells, implying a clinical benefit of FTO inhibition combined with anti-PD-1 blockade in overcoming the resistance in cancer immune checkpoint therapy (ICT) [189]. The gene discussed is FTO; the disease is cancer.